Artal Participations S.a r.l.
SEC insider (Form 3/4/5 filer). CIK 0002048403. Director at CAVA GROUP, INC. (CAVA) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 15, 2026. Located in LUXEMBOURG.
Companies Artal Participations S.a r.l. has filed insider reports for
- CAVA GROUP, INC. (CAVA): Director
- LEXICON PHARMACEUTICALS, INC. (LXRX): Director, 10% Owner
Artal Participations S.a r.l.
CIK: 0002048403
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (25.0%)
Position reduction
Option Exercises (M)1 (25.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 15, 2026CAVA
CAVA GROUP, INC.
SaleDirect3M shares at avg. $90.30$270.9M - Apr 30, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
ExerciseIndirect20.4M shares- - Apr 30, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
AwardIndirectSeries B Convertible Preferred Stock
408.4K shares- - Feb 17, 2026LXRX
LEXICON PHARMACEUTICALS, INC.
AwardIndirect41.3K shares at avg. $65.00$2.7M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 15, 2026 |  CAVA CAVA GROUP, INC. | Sale | 3,000,000 | $90.30 | $270,900,000 | Direct |
| Apr 30, 2026 |  LXRX LEXICON PHARMACEUTICALS, INC. | Exercise | 20,421,735 | - | $0 | Indirect |
| Apr 30, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award Series B Convertible Preferred Stock | 408,435 | - | - | Indirect |
| Feb 17, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | Award | 41,290 | $65.00 | $2,683,823 | Indirect |
1-4 of 4 transactions